Canadian consensus: Inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

Barbara Melosky; J. Agulnik; R. Albadine; S. Banerji; D. G. Bebb; D. Bethune; N. Blais; C. Butts; P. Cheema; P. Cheung; V. Cohen; J. Deschenes; D. N. Ionescu; R. Juergens; S. Kamel-Reid; S. A. Laurie; G. Liu; W. Morzycki; M. S. Tsao; Z. Xu; V. Hirsh

doi:10.3747/co.23.3120

Canadian consensus: Inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

Barbara Melosky, J. Agulnik, R. Albadine, S. Banerji, D. G. Bebb, D. Bethune, N. Blais, C. Butts, P. Cheema, P. Cheung, V. Cohen, J. Deschenes, D. N. Ionescu, R. Juergens, S. Kamel-Reid, S. A. Laurie, G. Liu, W. Morzycki, M. S. Tsao, Z. XuV. Hirsh

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Anaplastic lymphoma kinase (ALK) is an oncogenic driver in non-small-cell lung cancer (NSCLC). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead to constitutive activation of the alk signalling pathway. ALK-positive nsclc is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis. Targeted inhibition of the alk pathway prolongs progression-free survival in patients with ALK-positive advanced nsclc. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population. Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted alk inhibitor in the first-line setting is recommended. As patients become resistant to first-generation alk inhibitors, other treatments, including second-generation ALK inhibitors can be considered.

Original language	English
Pages (from-to)	196-200
Number of pages	5
Journal	Current Oncology
Volume	23
Issue number	3
DOIs	https://doi.org/10.3747/co.23.3120
Publication status	Published - 2016
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2016 Multimed Inc.

ASJC Scopus Subject Areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3747/co.23.3120

Cite this

Melosky, B., Agulnik, J., Albadine, R., Banerji, S., Bebb, D. G., Bethune, D., Blais, N., Butts, C., Cheema, P., Cheung, P., Cohen, V., Deschenes, J., Ionescu, D. N., Juergens, R., Kamel-Reid, S., Laurie, S. A., Liu, G., Morzycki, W., Tsao, M. S., ... Hirsh, V. (2016). Canadian consensus: Inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. Current Oncology, 23(3), 196-200. https://doi.org/10.3747/co.23.3120

Melosky, B, Agulnik, J, Albadine, R, Banerji, S, Bebb, DG, Bethune, D, Blais, N, Butts, C, Cheema, P, Cheung, P, Cohen, V, Deschenes, J, Ionescu, DN, Juergens, R, Kamel-Reid, S, Laurie, SA, Liu, G, Morzycki, W, Tsao, MS, Xu, Z & Hirsh, V 2016, 'Canadian consensus: Inhibition of ALK-positive tumours in advanced non-small-cell lung cancer', Current Oncology, vol. 23, no. 3, pp. 196-200. https://doi.org/10.3747/co.23.3120

@article{47064ae1e08d4ee9ba7a5f541a9ae993,

title = "Canadian consensus: Inhibition of ALK-positive tumours in advanced non-small-cell lung cancer",

abstract = "Anaplastic lymphoma kinase (ALK) is an oncogenic driver in non-small-cell lung cancer (NSCLC). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead to constitutive activation of the alk signalling pathway. ALK-positive nsclc is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis. Targeted inhibition of the alk pathway prolongs progression-free survival in patients with ALK-positive advanced nsclc. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population. Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted alk inhibitor in the first-line setting is recommended. As patients become resistant to first-generation alk inhibitors, other treatments, including second-generation ALK inhibitors can be considered.",

author = "Barbara Melosky and J. Agulnik and R. Albadine and S. Banerji and Bebb, {D. G.} and D. Bethune and N. Blais and C. Butts and P. Cheema and P. Cheung and V. Cohen and J. Deschenes and Ionescu, {D. N.} and R. Juergens and S. Kamel-Reid and Laurie, {S. A.} and G. Liu and W. Morzycki and Tsao, {M. S.} and Z. Xu and V. Hirsh",

note = "Publisher Copyright: {\textcopyright} 2016 Multimed Inc.",

year = "2016",

doi = "10.3747/co.23.3120",

language = "English",

volume = "23",

pages = "196--200",

journal = "Current Oncology",

issn = "1198-0052",

publisher = "Multimed Inc.",

number = "3",

}

TY - JOUR

T1 - Canadian consensus

T2 - Inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

AU - Melosky, Barbara

AU - Agulnik, J.

AU - Albadine, R.

AU - Banerji, S.

AU - Bebb, D. G.

AU - Bethune, D.

AU - Blais, N.

AU - Butts, C.

AU - Cheema, P.

AU - Cheung, P.

AU - Cohen, V.

AU - Deschenes, J.

AU - Ionescu, D. N.

AU - Juergens, R.

AU - Kamel-Reid, S.

AU - Laurie, S. A.

AU - Liu, G.

AU - Morzycki, W.

AU - Tsao, M. S.

AU - Xu, Z.

AU - Hirsh, V.

PY - 2016

Y1 - 2016

N2 - Anaplastic lymphoma kinase (ALK) is an oncogenic driver in non-small-cell lung cancer (NSCLC). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead to constitutive activation of the alk signalling pathway. ALK-positive nsclc is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis. Targeted inhibition of the alk pathway prolongs progression-free survival in patients with ALK-positive advanced nsclc. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population. Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted alk inhibitor in the first-line setting is recommended. As patients become resistant to first-generation alk inhibitors, other treatments, including second-generation ALK inhibitors can be considered.

AB - Anaplastic lymphoma kinase (ALK) is an oncogenic driver in non-small-cell lung cancer (NSCLC). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead to constitutive activation of the alk signalling pathway. ALK-positive nsclc is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis. Targeted inhibition of the alk pathway prolongs progression-free survival in patients with ALK-positive advanced nsclc. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population. Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted alk inhibitor in the first-line setting is recommended. As patients become resistant to first-generation alk inhibitors, other treatments, including second-generation ALK inhibitors can be considered.

UR - http://www.scopus.com/inward/record.url?scp=84974652861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974652861&partnerID=8YFLogxK

U2 - 10.3747/co.23.3120

DO - 10.3747/co.23.3120

M3 - Article

AN - SCOPUS:84974652861

SN - 1198-0052

VL - 23

SP - 196

EP - 200

JO - Current Oncology

JF - Current Oncology

IS - 3

ER -

Canadian consensus: Inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

Abstract

Bibliographical note

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this